- Molecular NameQuinapril
- SynonymQuinapril HCl; Quinapril Hydrochloride; Quinaprilum [Latin]
- Weight438.524
- Drugbank_IDDB00881
- ACS_NO85441-61-8
- Show 3D model
- LogP (experiment)3.384
- LogP (predicted, AB/LogP v2.0)2.65
- pkaN/A
- LogD (pH=7, predicted)-0.54
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.81
- LogSw (predicted, AB/LogsW2.0)0.78
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds10
- TPSA95.94
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure.
- Absorption_value60.0
- Absorption (description)Following oral administration, peak plasma quinapril concentrations are observed within one hour. Based on recovery of quinapril and its metabolites in urine, the extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding97.0
- Volume of distribution (VD)0.31 L/kg (range 0.18 to 0.52 L/kg) for patients undergoing haemodialysis; 0.3 (0.26 to 0.4) L/kg for those undergoing continuous peritoneal dialysis treatment.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHydrolyzed to its active metabolite, quinaprilat.
- Half life0.8~0.9 h
- ExcretionN/A
- Urinary Excretion3.1
- CleranceN/A
- ToxicityOverdose may lead to severe hypotension.
- LD50 (rat)N/A
- LD50 (mouse)LD50=1739 mg/kg